{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:15:06Z","timestamp":1791342906238,"version":"4.3.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00198-022-06455-2","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:20:22Z","timestamp":1659090022000},"page":"2397-2408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Sickle cell bone disease and response to intravenous bisphosphonates in children"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-7741","authenticated-orcid":false,"given":"C.","family":"Grimbly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6469-3510","authenticated-orcid":false,"given":"P. Diaz","family":"Escagedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Jaremko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5754-017X","authenticated-orcid":false,"given":"A.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1258-7665","authenticated-orcid":false,"given":"N.","family":"Alos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2539-227X","authenticated-orcid":false,"given":"M. E.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. N.","family":"Konji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scharke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6052-5904","authenticated-orcid":false,"given":"E.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. D.","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7396-7894","authenticated-orcid":false,"given":"R. T.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"6455_CR1","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMra1510865","volume":"376","author":"FB Piel","year":"2017","unstructured":"Piel FB, Steinberg MH, Rees DC (2017) Sickle cell disease. N Engl J Med 376:1561\u20131573. https:\/\/doi.org\/10.1056\/NEJMra1510865","journal-title":"N Engl J Med"},{"key":"6455_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.med.0000436192.25846.0b","volume":"20","author":"I Osunkwo","year":"2013","unstructured":"Osunkwo I (2013) An update on the recent literature on sickle cell bone disease. Curr Opin Endocrinol Diabetes Obes 20:539\u2013546. https:\/\/doi.org\/10.1097\/01.med.0000436192.25846.0b","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"6455_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jmbbm.2015.04.019","volume":"48","author":"M Green","year":"2015","unstructured":"Green M, Akinsami I, Lin A et al (2015) Microarchitectural and mechanical characterization of the sickle bone. J Mech Behav Biomed Mater 48:220\u2013228. https:\/\/doi.org\/10.1016\/j.jmbbm.2015.04.019","journal-title":"J Mech Behav Biomed Mater"},{"key":"6455_CR4","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1365-2141.2005.05476.x","volume":"129","author":"A Almeida","year":"2005","unstructured":"Almeida A, Roberts I (2005) Bone involvement in sickle cell disease. Br J Haematol 129:482\u2013490. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05476.x","journal-title":"Br J Haematol"},{"key":"6455_CR5","doi-asserted-by":"publisher","unstructured":"Adekile AD, Gupta R, Al-Khayat A, et al (2018) Risk of avascular necrosis of the femoral head in children with sickle cell disease on hydroxyurea: MRI evaluation. Pediatr Blood Cancer 1\u20135https:\/\/doi.org\/10.1002\/pbc.27503","DOI":"10.1002\/pbc.27503"},{"key":"6455_CR6","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1056\/NEJM199111213252104","volume":"325","author":"PF Milner","year":"1991","unstructured":"Milner PF, Kraus AP, Sebes JI et al (1991) Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 325:1476\u20131481. https:\/\/doi.org\/10.1056\/NEJM199111213252104","journal-title":"N Engl J Med"},{"key":"6455_CR7","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.2106\/JBJS.E.01455","volume":"88","author":"PH Hernigou","year":"2006","unstructured":"Hernigou PH, Habibi A, Bachir D, Galacteros F (2006) The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. J bone Jt Surg 88:2565","journal-title":"J bone Jt Surg"},{"key":"6455_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1182\/bloodadvances.2017005256","volume":"1","author":"O Adesina","year":"2017","unstructured":"Adesina O, Brunson A, Keegan THM, Wun T (2017) Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California. Blood Adv 1:1287\u20131295. https:\/\/doi.org\/10.1182\/bloodadvances.2017005256","journal-title":"Blood Adv"},{"key":"6455_CR9","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","volume":"312","author":"BP Yawn","year":"2014","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN et al (2014) Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA - J Am Med Assoc 312:1033\u20131048","journal-title":"JAMA - J Am Med Assoc"},{"key":"6455_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1302\/0301-620X.73B6.1955442","volume":"73","author":"HE Ware","year":"1991","unstructured":"Ware HE, Brooks AP, Toye R, Berney SI (1991) Sickle cell disease and silent avascular necrosis of the hip. J Bone Joint Surg Br 73:947\u2013949","journal-title":"J Bone Joint Surg Br"},{"key":"6455_CR11","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/BF00357859","volume":"27","author":"VC Ejindu","year":"2007","unstructured":"Ejindu VC, Hine MAL, Mohammad F et al (2007) Musculoskeletal manifestations of sickle cell disease. Radiographics 27:1005\u20131022. https:\/\/doi.org\/10.1007\/BF00357859","journal-title":"Radiographics"},{"key":"6455_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00247-014-3210-y","volume":"45","author":"JL Jaremko","year":"2015","unstructured":"Jaremko JL, Siminoski K, Firth GB et al (2015) Common normal variants of pediatric vertebral development that mimic fractures: a pictorial review from a national longitudinal bone health study. Pediatr Radiol 45:593\u2013605","journal-title":"Pediatr Radiol"},{"key":"6455_CR13","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.hoc.2005.07.001","volume":"19","author":"C Aguilar","year":"2005","unstructured":"Aguilar C, Vichinsky E, Neumayr L (2005) Bone and joint disease in sickle cell disease. Hematol Oncol Clin North Am 19:929\u2013941. https:\/\/doi.org\/10.1016\/j.hoc.2005.07.001","journal-title":"Hematol Oncol Clin North Am"},{"key":"6455_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.12659\/AJCR.900538","volume":"18","author":"LP Turaga","year":"2017","unstructured":"Turaga LP, Boddu P, Kipferl S et al (2017) Myonecrosis in sickle cell anemia case study. Am J Case Rep 18:100\u2013103. https:\/\/doi.org\/10.12659\/AJCR.900538","journal-title":"Am J Case Rep"},{"key":"6455_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/659031","volume":"2010","author":"N Tageja","year":"2010","unstructured":"Tageja N, Racovan M, Valent J, Zonder J (2010) Myonecrosis in sickle cell anemia\u2014overlooked and underdiagnosed. Case Rep Med 2010:1\u20133. https:\/\/doi.org\/10.1155\/2010\/659031","journal-title":"Case Rep Med"},{"key":"6455_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/0002-9343(93)90336-n","volume":"95","author":"S Mani","year":"1993","unstructured":"Mani S, Duffy TP (1993) Sickle myonecrosis revisited. Am J Med 95:525\u2013530. https:\/\/doi.org\/10.1016\/0002-9343(93)90336-n","journal-title":"Am J Med"},{"key":"6455_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/MPH.0000000000001306","volume":"40","author":"P Gr\u00e9goire-Pelchat","year":"2018","unstructured":"Gr\u00e9goire-Pelchat P, Alos N, Ribault V et al (2018) Vitamin D intake and status of children with sickle cell disease in Montreal, Canada. J Pediatr Hematol Oncol 40:531\u2013536. https:\/\/doi.org\/10.1097\/MPH.0000000000001306","journal-title":"J Pediatr Hematol Oncol"},{"key":"6455_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002068","author":"RKS Wong","year":"2009","unstructured":"Wong RKS, Wiffen PJ (2009) Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD002068","journal-title":"Cochrane Database Syst Rev"},{"key":"6455_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22681","author":"KJ August","year":"2011","unstructured":"August KJ, Dalton A, Katzenstein HM et al (2011) The use of zoledronic acid in pediatric cancer patients. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.22681","journal-title":"Pediatr Blood Cancer"},{"key":"6455_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1102-9","volume":"14","author":"MK Javaid","year":"2019","unstructured":"Javaid MK, Boyce A, Appelman-Dijkstra N et al (2019) Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium. Orphanet J Rare Dis 14:1\u201317. https:\/\/doi.org\/10.1186\/s13023-019-1102-9","journal-title":"Orphanet J Rare Dis"},{"key":"6455_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.645","author":"B Padhye","year":"2016","unstructured":"Padhye B, Dalla-Pozza L, Little D, Munns C (2016) Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL). Cancer Med. https:\/\/doi.org\/10.1002\/cam4.645","journal-title":"Cancer Med"},{"key":"6455_CR22","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3390\/jcm9051601","volume":"9","author":"L De Franceschi","year":"2020","unstructured":"De Franceschi L, Gabbiani D, Giusti A et al (2020) Development of algorithm for clinical management of sickle cell bone disease: evidence for a role of vertebral fractures in patient follow-up. J Clin Med 9:1601. https:\/\/doi.org\/10.3390\/jcm9051601","journal-title":"J Clin Med"},{"issue":"600","key":"6455_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2012-eular.3327","volume":"71","author":"T BackaCico","year":"2013","unstructured":"BackaCico T, Kullolli S, Harizi I et al (2013) SAT0381 The use of bisphosphonates in the treatment of low bone mineral density in adults with sickle cell anemia. Ann Rheum Dis 71(600):3\u2013601. https:\/\/doi.org\/10.1136\/annrheumdis-2012-eular.3327","journal-title":"Ann Rheum Dis"},{"key":"6455_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.yped.2016.08.050","volume":"56","author":"C Munns","year":"2016","unstructured":"Munns C, Shaw N, Kiely M et al (2016) Global consensus recommendations on prevention and management of nutrition rickets. Pediatriya 56:60\u201363. https:\/\/doi.org\/10.1016\/j.yped.2016.08.050","journal-title":"Pediatriya"},{"key":"6455_CR25","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s00198-016-3515-9","volume":"27","author":"LM Ward","year":"2016","unstructured":"Ward LM, Konji VN, Ma J (2016) The management of osteoporosis in children. Osteoporos Int 27:2147\u20132179. https:\/\/doi.org\/10.1007\/s00198-016-3515-9","journal-title":"Osteoporos Int"},{"key":"6455_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.bone.2019.01.003","volume":"121","author":"N Nasomyont","year":"2019","unstructured":"Nasomyont N, Hornung LN, Gordon CM, Wasserman H (2019) Outcomes following intravenous bisphosphonate infusion in pediatric patients: a 7-year retrospective chart review. Bone 121:60\u201367. https:\/\/doi.org\/10.1016\/j.bone.2019.01.003","journal-title":"Bone"},{"key":"6455_CR27","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1359\/jbmr.090202","volume":"24","author":"J Halton","year":"2009","unstructured":"Halton J, Gaboury I, Grant R et al (2009) Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program. J Bone Miner Res 24:1326\u20131334. https:\/\/doi.org\/10.1359\/jbmr.090202","journal-title":"J Bone Miner Res"},{"key":"6455_CR28","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1210\/jc.2011-1111","volume":"96","author":"BS Zemel","year":"2011","unstructured":"Zemel BS, Kalkwarf HJ, Gilsanz V et al (2011) Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab 96:3160\u20133169. https:\/\/doi.org\/10.1210\/jc.2011-1111","journal-title":"J Clin Endocrinol Metab"},{"key":"6455_CR29","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1210\/jc.2009-2057","volume":"95","author":"BS Zemel","year":"2010","unstructured":"Zemel BS, Leonard MB, Kelly A et al (2010) Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab 95:1265\u20131273. https:\/\/doi.org\/10.1210\/jc.2009-2057","journal-title":"J Clin Endocrinol Metab"},{"key":"6455_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S8756-3282(99)00257-4","volume":"26","author":"FH Glorieux","year":"2000","unstructured":"Glorieux FH, Travers R, Taylor A et al (2000) Normative data for iliac bone histomorphometry in growing children. Bone 26:103\u2013109. https:\/\/doi.org\/10.1016\/S8756-3282(99)00257-4","journal-title":"Bone"},{"key":"6455_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000046529","volume":"105","author":"AD Adekile","year":"2001","unstructured":"Adekile AD, Gupta R, Yacoub F et al (2001) Avascular necrosis of the hip in children with sickle cell disease and high Hb F: magnetic resonance imaging findings and influence of \u03b1-thalassemia trait. Acta Haematol 105:27\u201331. https:\/\/doi.org\/10.1159\/000046529","journal-title":"Acta Haematol"},{"key":"6455_CR32","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.apmr.2005.01.008","volume":"86","author":"CM Aguilar","year":"2005","unstructured":"Aguilar CM, Neumayr LD, Eggleston BE et al (2005) Clinical evaluation of avascular necrosis in patients with sickle cell disease: children\u2019s hospital oakland hip evaluation scale - a modification of the harris hip score. Arch Phys Med Rehabil 86:1369\u20131375. https:\/\/doi.org\/10.1016\/j.apmr.2005.01.008","journal-title":"Arch Phys Med Rehabil"},{"key":"6455_CR33","doi-asserted-by":"publisher","unstructured":"Mesleh Shayeb A, Smeltzer MP, Kaste SC, et al (2018) Vaso-occlusive crisis as a predictor of symptomatic avascular necrosis in children with sickle cell disease. Pediatr Blood Cancer 1\u20134https:\/\/doi.org\/10.1002\/pbc.27435","DOI":"10.1002\/pbc.27435"},{"key":"6455_CR34","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1051\/mbcb\/2020039","volume":"27","author":"T Roland-Billecart","year":"2021","unstructured":"Roland-Billecart T, Maes JM, Vieillard MH et al (2021) Avascular necrosis of the jaw resulting from sickle cell disease. J Oral Med Oral Surg 27:2020\u20132022. https:\/\/doi.org\/10.1051\/mbcb\/2020039","journal-title":"J Oral Med Oral Surg"},{"key":"6455_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405","journal-title":"J Bone Miner Res"},{"key":"6455_CR36","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1172\/JCI0215952","volume":"110","author":"F Rauch","year":"2002","unstructured":"Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293\u20131299. https:\/\/doi.org\/10.1172\/JCI0215952","journal-title":"J Clin Invest"},{"key":"6455_CR37","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1007\/s00198-012-1911-3","volume":"23","author":"AM Sbrocchi","year":"2012","unstructured":"Sbrocchi AM, Rauch F, Jacob P et al (2012) The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int 23:2703\u20132711. https:\/\/doi.org\/10.1007\/s00198-012-1911-3","journal-title":"Osteoporos Int"},{"key":"6455_CR38","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/jbmr.2567","volume":"30","author":"T Palomo","year":"2015","unstructured":"Palomo T, Fassier F, Ouellet J et al (2015) Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res 30:2150\u20132157. https:\/\/doi.org\/10.1002\/jbmr.2567","journal-title":"J Bone Miner Res"},{"key":"6455_CR39","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H et al (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947\u2013952. https:\/\/doi.org\/10.1056\/NEJM199810013391402","journal-title":"N Engl J Med"},{"key":"6455_CR40","doi-asserted-by":"publisher","first-page":"E160","DOI":"10.1002\/ajh.25453","volume":"94","author":"NP Itzep","year":"2019","unstructured":"Itzep NP, Jadhav SP, Kanne CK, Sheehan VA (2019) Spontaneous healing of avascular necrosis of the femoral head in sickle cell disease. Am J Hematol 94:E160\u2013E162. https:\/\/doi.org\/10.1002\/ajh.25453","journal-title":"Am J Hematol"},{"key":"6455_CR41","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1182\/hematology.2020000143","volume":"2020","author":"I Osunkwo","year":"2020","unstructured":"Osunkwo I, O\u2019Connor HF, Saah E (2020) Optimizing the management of chronic pain in sickle cell disease. Hematol Am Soc Hematol Educ Progr 2020:562\u2013569. https:\/\/doi.org\/10.1182\/hematology.2020000143","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"6455_CR42","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1080\/14656566.2019.1612367","volume":"20","author":"G Iolascon","year":"2019","unstructured":"Iolascon G, Moretti A (2019) Pharmacotherapeutic options for complex regional pain syndrome. Expert Opin Pharmacother 20:1377\u20131386. https:\/\/doi.org\/10.1080\/14656566.2019.1612367","journal-title":"Expert Opin Pharmacother"},{"key":"6455_CR43","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.hoc.2018.01.006","volume":"32","author":"N Figura","year":"2018","unstructured":"Figura N, Smith J, Yu HHM (2018) Mechanisms of, and adjuvants for, bone pain. Hematol Oncol Clin North Am 32:447\u2013458. https:\/\/doi.org\/10.1016\/j.hoc.2018.01.006","journal-title":"Hematol Oncol Clin North Am"},{"key":"6455_CR44","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40272-017-0226-4","volume":"19","author":"A Taddio","year":"2017","unstructured":"Taddio A, Zennaro F, Pastore S, Cimaz R (2017) An update on the pathogenesis and treatment of chronic recurrent multifocal osteomyelitis in children. Pediatr Drugs 19:165\u2013172. https:\/\/doi.org\/10.1007\/s40272-017-0226-4","journal-title":"Pediatr Drugs"},{"key":"6455_CR45","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11914-017-0405-9","volume":"15","author":"SR Hofmann","year":"2017","unstructured":"Hofmann SR, Kapplusch F, Girschick HJ et al (2017) Chronic recurrent multifocal osteomyelitis (CRMO): presentation, pathogenesis, and treatment. Curr Osteoporos Rep 15:542\u2013554. https:\/\/doi.org\/10.1007\/s11914-017-0405-9","journal-title":"Curr Osteoporos Rep"},{"key":"6455_CR46","doi-asserted-by":"publisher","unstructured":"Ku\u017anik A, Pa\u017adzierniok-Holewa A, Jewula P, Ku\u017anik N (2020) Bisphosphonates\u2014much more than only drugs for bone diseases. Eur J Pharmacol 866https:\/\/doi.org\/10.1016\/j.ejphar.2019.172773","DOI":"10.1016\/j.ejphar.2019.172773"},{"key":"6455_CR47","doi-asserted-by":"publisher","first-page":"154933","DOI":"10.1016\/j.cyto.2019.154933","volume":"127","author":"EA Barbu","year":"2020","unstructured":"Barbu EA, Mendelsohn L, Samsel L, Thein SL (2020) Pro-inflammatory cytokines associate with NETosis during sickle cell vaso-occlusive crises. Cytokine 127:154933. https:\/\/doi.org\/10.1016\/j.cyto.2019.154933","journal-title":"Cytokine"},{"key":"6455_CR48","doi-asserted-by":"publisher","unstructured":"Dalle Carbonare L, Matte A, Teresa Valenti M, et al (2015) Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone diseasehttps:\/\/doi.org\/10.1182\/blood-2015-04","DOI":"10.1182\/blood-2015-04"},{"key":"6455_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph18041832","volume":"18","author":"P Giordano","year":"2021","unstructured":"Giordano P, Urbano F, Lassandro G, Faienza MF (2021) Mechanisms of bone impairment in sickle bone disease. Int J Environ Res Public Health 18:1\u201311. https:\/\/doi.org\/10.3390\/ijerph18041832","journal-title":"Int J Environ Res Public Health"},{"key":"6455_CR50","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.22103","volume":"86","author":"KM Mahadeo","year":"2011","unstructured":"Mahadeo KM, Oyeku S, Taragin B et al (2011) Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease. Am J Hematol 86:806\u2013808. https:\/\/doi.org\/10.1002\/ajh.22103","journal-title":"Am J Hematol"},{"key":"6455_CR51","doi-asserted-by":"publisher","unstructured":"Adekile AD, Gupta R, Al-Khayat A, et al (2019) Risk of avascular necrosis of the femoral head in children with sickle cell disease on hydroxyurea: MRI evaluation. Pediatr Blood Cancer 66https:\/\/doi.org\/10.1002\/pbc.27503","DOI":"10.1002\/pbc.27503"},{"key":"6455_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","volume":"390","author":"RE Ware","year":"2017","unstructured":"Ware RE, de Montalembert M, Tshilolo L, Abboud MR (2017) Sickle cell disease. Lancet 390:311\u2013323","journal-title":"Lancet"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06455-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06455-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06455-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T06:12:23Z","timestamp":1665727943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06455-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["6455"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06455-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"13 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University of Alberta, CHEO, and CHU St. Justine Research Ethics boards. The study has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"CG has been a consultant to Ultragenyx and IPSEN. LMW has been a consultant to, and participated in clinical trials with, Ultragenyx, Novartis, and Amgen (with funds to Dr. Ward\u2019s institution). NA has participated in clinical trials with Novartis, Amgen, Europharm, and Levo therapeutics. MER has been a consultant to Ultragenyx and IPSEN and has received a research grant from Ascendis Biopharma. YDP has been a consultant to and participated in clinical trials with Novartis, Agios, Forma Pharmaceutic, and Principia. RG has been a consultant to IPSEN and Pfizer and has received research grants from Novo-Nordisk and Ascendis. PDE, JLJ, AB, VNK, MP, MS, and ES declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}